ASCEND Therapeutics, Inc. to Present at BIO 2003 Annual Convention.Business Editors/Health/Medical Writers BIOWIRE2K BIO 2003 Annual Convention HERNDON, Va.--(BUSINESS WIRE)--June 20, 2003 ASCEND Therapeutics announced today that Jay A Bua, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ASCEND Therapeutics, Inc., is scheduled to give an update on the Company's strategy and product pipeline utilizing its proven Enhanced Hydroalcoholic Gel Technology (EHG(TM)) at the BIO 2003 Annual Convention on Wednesday, June 26, 2003 at the Washington Convention Center The Washington Convention Center has been the name of two convention centers in Washington, D.C. The old Washington Convention Center was located at 909 H Street NW and was in use from 1983 until 2004. in Washington, D.C. Bua's presentation is scheduled for 8:45 AM EDT. The presentation will be webcast and can be accessed on the Company's web site at http://www.ascend.com. Based in Herndon, Virginia, ASCEND Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative therapeutic products for the treatment of underserved chronic conditions. ASCEND is focused on developing transdermal drug products spanning several therapeutic areas, including endocrinology, oncologic chemoprevention che·mo·pre·ven·tion n. The use of chemical agents, drugs, or food supplements to prevent disease. chemoprevention , and dermatology. ASCEND's initial products include TamoGel(TM) for symptoms of benign breast disease benign breast disease See Fibroadenoma, Fibrocystic disease, Mastopathy. , and Andrin(TM) for elderly hypogonadism Hypogonadism Definition Hypogonadism is the condition more prevalent in males in which the production of sex hormones and germ cells are inadequate. . TamoGel(TM) is currently in two separate Phase II clinical trials to evaluate its impact on cyclic breast pain and mammographic breast density. Andrin(TM) will begin a Phase II trial in the next few months. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion